Following last month’s dismissal of the Amgen v. Kashiv filgrastim biosimilar litigation, yesterday Amgen and Tanvex filed a joint stipulation of dismissal in their BPCIA litigation concerning Tanvex’s filgrastim biosimilar candidate. The stipulation states that the parties agree “to the dismissal, without prejudice, of all remaining claims and counterclaims in…
On July 23, 2019, Amgen sued Tanvex BioPharma USA, Inc. and two of its affiliates in the Southern District of California alleging infringement of U.S. Patent No. 9,856,287 under the BPCIA based on Tanvex’s submission of an aBLA for a biosimilar of NEUPOGEN (filgrastim). As relief, Amgen’s complaint requests, among…
Pending U.S. District Court BPCIA Litigations Litigation Accused Biosimilar [status] Reference Product Complaint Filed Status/Outcome District Court Appeal Genentech, Inc. v. Tanvex Biopharma USA, Inc. et al. No. 1:22-CV-0809 (S.D. Cal.) TX05 (trastuzumab) [not approved] HERCEPTIN June 2, 2022 Pending Regeneron Pharmaceuticals, Inc. v. Mylan Pharmaceuticals Inc. No. 1:22-cv-00061 (D….